Clinical trials: Vascular And Immunologic Diseases
Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes
Type 1 Diabetes Autonomic and Vascular Function
The goal of this clinical trial is to investigate the autonomic and vascular function in men and women with Type 1 diabetes. The main questions it aims to answer are: 1.
- Conditions
- Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Diabetes, Autoimmune
- Trial name
- NCT06786546
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Chronic Myeloproliferative Disorders, Leukemia
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes
- Trial name
- NCT00005622
- Testing
- cyclophosphamide, TBI
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
- Trial name
- NCT06153251
- Testing
- BMS-986453, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, France and 2 more
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01676961
- Testing
- romiplostim
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Waldenstrom Macroglobulinaemia, Multiple Myeloma
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
- Trial name
- BLOOD-dose (NCT07474961)
- Testing
- teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib)
- Where
- 5 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Anne Louise Tølbøll Sørensen
Multiple Myeloma
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk…
- Trial name
- NCT03104842
- Testing
- Isatuximab, Carfilzomib, Lenalidomide
- Where
- 17 sites in Germany
- Volunteers
- 246 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Myeloma
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM.
- Trial name
- MyHOPE™ (NCT04730505)
- Testing
- MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
- Where
- 34 sites in United States
- Volunteers
- 2 people
- Sponsor
- Celgene
Multiple Myeloma
Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse
In patients with Multiple Myeloma (MM), bone lesions can lead to multiple vertebral lesions, with vertebral collapses. The introduction of minimally invasive procedures such as percutaneous vertebroplasty allow patients to return…
- Trial name
- NCT06255639
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01096342
- Testing
- dinaciclib, laboratory biomarker analysis
- Where
- 6 sites in United States, Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Cutaneous Lymphoma
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients undergoing high dose therapy for the treatment of a range of cancers.
- Trial name
- NCT00400556
- Testing
- ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Multiple Myeloma
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
This study will observe the degree of the quality of life in non-transplant candidate patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and…
- Trial name
- NCT01060202
- Testing
- No intervention
- Volunteers
- 60 people
- Sponsor
- Janssen Korea, Ltd., Korea
Lymphoma, Quality of Life
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.
- Trial name
- NCT00098566
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Lymphoma
A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
Hematopoietic stem cells (HSC) are used to support the administration of high dose chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5 million HSC per kilogram are required.
- Trial name
- NCT00234169
- Testing
- VTP195183
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
The outcomes in patients with relapsed or refractory multiple myeloma refractory to triple-therapy remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous…
- Trial name
- NCT07200102
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Giant Cell Arteritis
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg bodyweight i.v.
- Trial name
- GUSTO (NCT03745586)
- Testing
- Tocilizumab, Glucocorticoids
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Granulomatosis With Polyangiitis, Wegener Granulomatosis
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose glucocorticoids ( 5 mg/day of prednisone) as…
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
- Trial name
- TAPIR (NCT01933724)
- Testing
- 5 mg prednisone, 0 mg prednisone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Multiple Myeloma
VitD3 Supplementation in Patients With Multiple Myeloma
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms.
- Trial name
- NCT05846880
- Testing
- Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Amany Keruakous, MD, MS.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.